2L
ELDN icon

22NW LP’s Eledon Pharmaceuticals ELDN Stock Holding History

22NW LP’s Portfolio ELDN Stock Details ELDN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.51M Hold
636,364
– – 2.4% 12
2026
Q1 		$1.96M Hold
636,364
– – 1.34% 15
2025
Q4 		$961K Hold
636,364
– – 0.4% 18
2025
Q3 		$1.65M Hold
636,364
– – 0.78% 19
2025
Q2 		$1.72M Hold
636,364
– – 1.09% 19
2025
Q1 		$2.16M Buy
+636,364
New +$2.62M 1.45% 14

Other funds holding ELDN

BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DCM
Defilade Capital Management Emeryville, California $747M AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Ensign Peak Advisors
Ensign Peak Advisors Salt Lake City, Utah $60.8B AUM 42.06% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
CCM
Catalio Capital Management New York $532M AUM 171.17% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
ZP
Zimmer Partners New York $4.34B AUM 22.78% 1-Year Est. Return

22NW LP's ELDN Position: Q2 2026 in Review

22NW LP held its Eledon Pharmaceuticals (ELDN) position steady in Q2 2026 at 636,364 shares worth $2.51M. The position accounts for 2.4% of the portfolio, ranked #12.

22NW LP first reported a position in ELDN in Q1 2025 and has held it in 6 quarters since. 161 funds tracked by Wall St. Rank hold ELDN as of Q2 2026.

  • 22NW LP held 636,364 shares of Eledon Pharmaceuticals worth $2.51M as of Q2 2026.
  • 22NW LP left its Eledon Pharmaceuticals share count unchanged in Q2 2026.
  • Eledon Pharmaceuticals made up 2.4% of 22NW LP's portfolio in Q2 2026, its #12 holding.
  • 22NW LP first reported a position in Eledon Pharmaceuticals in Q1 2025 and has held it in 6 quarters since.
  • 161 funds tracked by Wall St. Rank held Eledon Pharmaceuticals as of Q2 2026.

Based on 22NW LP's 13F filing for Q2 2026, filed 14 Aug 2026.